Physicians' Academy for Cardiovascular Education

Contemporary management of a patient with heart failure and diabetes: Implications from recent trials

Meeting report with video, highlights and slides of a PACE-CME symposium held at the ESC congress Heart Failure 2018 in Vienna. More information will be added

Meeting Impression | Contemporary management of a patient with heart failure and diabetes: Implications from recent trials

May 28, 2018 – Vienna, Austria
May 28, 2018 – Vienna, Austria

Download the meeting impression of this PACE symposium during Heart Failure 2018, which considered what recent outcome trials with glucose-lowering trials can tell us about us about optimal management of patients with HF and diabetes.

Summary | Guidance from outcome trials: What are the clinical implications

Vienna, Austria - May 28, 2018

Prof. Zannad compared the clinical outcomes in trials of various novel classes of glucose-lowering drugs, to postulate what these findings may tell us about their mechanism of action, and how they can be benefitted from in the management of patients with HF and diabetes.

Summary | Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

Vienna, Austria - May 28, 2018

Prof. Sattar looked at the data of recent outcome trials to postulate how they might work to exert the observed clinical benefit. Altered hemodynamics likely importantly contribute to the benefits on HF outcomes.

Summary | Current management of heart failure & T2DM

Vienna, Austria - May 28, 2018

Prof. Cowie reflected on what good care for heart failure patients with diabetes should entail, and concludes that minimal care for diabetes does not differ so much from minimal standard care in HF practice.

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME
Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.

Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK - Online CME
Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.

Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France - Online CME
Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.

Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.

Slides: Guidance from outcome trials: What are the clinical implications?

Presentation prof. Faiez Zannad

Slides (presentation) - May 28, 2018 - ESC Heart Failure 2018, Vienna - Prof. Faiez Zannad - Paris, France
This lecture by prof Faiez Zannad was part of a CME accredited symposium: Contemporary management of a patient with Heart Failure and diabetes: Implications from recent trials?' held at ESC Heart Failure 2018 in Vienna.

Slides as educational service to PACE members and meeting participants.

Slides: Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

Presentation Prof. Naveed Sattar

Slides (presentation) - May 28, 2018 - ESC Heart Failure 2018, Vienna - Prof. Naveed Sattar - Glasgow, UK
This lecture by prof Naveed Sattar was part of a CME accredited symposium: **Contemporary management of a patient with Heart Failure and diabetes: Implications from recent trials?'** held at ESC Heart Failure 2018 in Vienna

Slides as educational service to PACE members and meeting participants

Slides: Current management of Heart Failure & T2DM

Presentation Prof. Martin Cowie

Slides (presentation) - May 28, 2018 - ESC Heart Failure 2018, Vienna - Prof. Martin Cowie, MD - London, UK
This lecture by prof Martin Cowie was part of a CME accredited symposium: Contemporary management of a patient with Heart Failure and diabetes: Implications from recent trials?' held at ESC Heart Failure 2018 in Vienna

Slides as educational service to PACE members and meeting participants

Contemporary management of a patient with heart failure and diabetes: Implications from recent trials
Contemporary management of a patient with heart failure and diabetes: Implications from recent trials